{"entity":{"id":"1988","kind":"year","name":"1988 in oncology","aka":["1988"],"tldr":"Everything OnCo dates to 1988: 26 entries, 11 landmarks, 4 approvals, 3 companies founded and 3 papers. Each line links to the record it was read from, so the year is a view of the corpus rather than a second copy of it.","summary":"26 dated entries in OnCo fall in 1988: 11 landmarks, 4 approvals, 3 companies founded, 3 papers, 3 papers listed on people's pages and 2 journals founded.\n\nOf those, 26 to the year only. Most of the corpus dates a fact to the year, because that is what the source it was read from gives; regulatory events and the readout calendar are the parts that carry a full date.\n\nEverything on this page is generated from the other records. It holds no fact of its own, and it changes when they do.","asOf":"2026-09-25","links":[],"tags":[],"related":["1987","1989"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Generated from every dated field in the corpus, not written by hand. The groups and the fields behind them are listed in src/lib/year-groups.ts; the reader is src/lib/years.ts."],"year":1988,"events":[{"group":"approval","date":"1988","precision":"year","title":"Ifosfamide approved in US","note":"Germ cell testicular cancer; widely used off-label in sarcoma","from":"ifosfamide","refs":[]},{"group":"approval","date":"1988","precision":"year","title":"Interferon alfa-2a/2b approved in US","note":"AIDS-related Kaposi sarcoma","from":"interferon-alfa","refs":[]},{"group":"approval","date":"1988","precision":"year","title":"Mesna approved in US","note":"Prophylaxis of ifosfamide-induced haemorrhagic cystitis (oral tablets 2002)","from":"mesna","refs":[]},{"group":"approval","date":"1988","precision":"year","title":"Somatostatin analogues (octreotide, lanreotide) approved in US","note":"Carcinoid syndrome symptoms (octreotide)","from":"octreotide-lanreotide","refs":[]},{"group":"company","date":"1988","precision":"year","title":"AngioDynamics founded","note":"Latham, NY","from":"angiodynamics","refs":[]},{"group":"company","date":"1988","precision":"year","title":"Oncotherm founded","note":"Troisdorf","from":"oncotherm","refs":[]},{"group":"company","date":"1988","precision":"year","title":"Telik founded","note":"Palo Alto, CA","from":"telik","refs":[]},{"group":"history","date":"1988","precision":"year","title":"All-trans retinoic acid produces remissions in Shanghai: the first differentiation therapy","note":"Acute promyelocytic leukaemia","from":"apl","refs":["tretinoin-atra"]},{"group":"history","date":"1988","precision":"year","title":"ATRA induces differentiation in APL","note":"Acute myeloid leukaemia. Shanghai group shows all-trans retinoic acid remissions; arsenic follows in the 1990s. First differentiation therapy.","from":"aml","refs":["differentiation-syndrome"]},{"group":"history","date":"1988","precision":"year","title":"Cyclophosphamide, vincristine and dacarbazine chemotherapy reported at the NIH","note":"Metastatic pheochromocytoma and paraganglioma","from":"metastatic-ppgl","refs":["cyclophosphamide","vincristine"]},{"group":"history","date":"1988","precision":"year","title":"Hyams grading of esthesioneuroblastoma","note":"Nasal cavity and paranasal sinus cancers (including esthesioneuroblastoma)","from":"sinonasal","refs":[]},{"group":"history","date":"1988","precision":"year","title":"Hyams grading system introduced","note":"Esthesioneuroblastoma (olfactory neuroblastoma)","from":"esthesioneuroblastoma","refs":[]},{"group":"history","date":"1988","precision":"year","title":"KRAS codon 12 mutations in 21 of 22 pancreatic cancers","note":"Pancreatic ductal adenocarcinoma. Almoguera and Perucho, by polymerase chain reaction; the most uniform driver in any common cancer.","from":"pancreatic","refs":["paper-almoguera-kras-codon-12-pancreatic-cell-1988","kras"]},{"group":"history","date":"1988","precision":"year","title":"KRAS mutations found in almost all pancreatic adenocarcinomas (Almoguera and Perucho)","note":"KRAS G12C-mutant pancreatic ductal adenocarcinoma","from":"kras-g12c-pdac","refs":["kras","oncogene"]},{"group":"history","date":"1988","precision":"year","title":"Octreotide approved for carcinoid syndrome","note":"Neuroendocrine tumours","from":"neuroendocrine","refs":["octreotide-lanreotide"]},{"group":"history","date":"1988","precision":"year","title":"Octreotide approved for carcinoid syndrome symptoms","note":"Small intestinal neuroendocrine tumours","from":"small-intestinal-net","refs":["octreotide-lanreotide"]},{"group":"history","date":"1988","precision":"year","title":"Pleuropulmonary blastoma described as a distinct entity","note":"Childhood lung and airway tumours (pleuropulmonary blastoma, tracheobronchial tumours). Manivel and colleagues separate PPB from adult pulmonary blastoma; the International PPB Reg...","from":"pleuropulmonary-blastoma","refs":[]},{"group":"history","date":"1988","precision":"year","title":"The genetic model of colorectal tumourigenesis","note":"Colorectal cancer. Four alterations measured across 172 specimens accumulate in step with progression: ras in 58% of adenomas over 1 cm, 18q loss in 73% of carcinomas, 17p loss alm...","from":"colorectal","refs":["paper-vogelstein-genetic-alterations-colorectal-tumor-development-nejm-1988","apc","kras"]},{"group":"journal","date":"1988","precision":"year","title":"Klinická onkologie founded","note":"Czech Medical Association of J. E. Purkyně (Care Comm s.r.o.)","from":"klinicka-onkologie","refs":[]},{"group":"journal","date":"1988","precision":"year","title":"Molecular carcinogenesis founded","note":"Wiley","from":"molecular-carcinogenesis","refs":[]},{"group":"paper","date":"1988","precision":"year","title":"Genetic alterations during colorectal-tumor development","note":"Vogelstein B, Fearon ER, Hamilton SR, et al. New England Journal of Medicine.","from":"paper-vogelstein-genetic-alterations-colorectal-tumor-development-nejm-1988","refs":[]},{"group":"paper","date":"1988","precision":"year","title":"Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes","note":"Almoguera C, Shibata D, Forrester K, et al. Cell.","from":"paper-almoguera-kras-codon-12-pancreatic-cell-1988","refs":[]},{"group":"paper","date":"1988","precision":"year","title":"The hazard of accelerated tumor clonogen repopulation during radiotherapy","note":"Withers HR, Taylor JM, Maciejewski B. Acta oncologica.","from":"paper-withers-acta-oncol","refs":[]},{"group":"person-paper","date":"1988","precision":"year","title":"A Letter from Dr. Elisabeth Kubler-Ross","note":"Journal of Palliative Care","from":"elisabeth-kubler-ross","refs":[]},{"group":"person-paper","date":"1988","precision":"year","title":"Activation of cdc2 protein kinase during mitosis in human cells: cell cycle-dependent phosphorylation and subunit rearrangement","note":"Cell","from":"giulio-draetta","refs":[]},{"group":"person-paper","date":"1988","precision":"year","title":"Human cdc2 protein kinase is a major cell-cycle regulated tyrosine kinase substrate","note":"Nature","from":"giulio-draetta","refs":[]}]},"route":"/years/1988/","neighbours":{"year":[{"id":"1987","kind":"year","name":"1987 in oncology","route":"/years/1987/"},{"id":"1989","kind":"year","name":"1989 in oncology","route":"/years/1989/"}]}}